Home » Stiefel Enters Agreement With Welichem Biotech to Acquire Topical Agent for Psoriasis, Atopic Dermatitis
Stiefel Enters Agreement With Welichem Biotech to Acquire Topical Agent for Psoriasis, Atopic Dermatitis
Stiefel, a GSK company, and Welichem Biotech have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong.
MarketWatch
MarketWatch
Upcoming Events
-
07May
-
14May
-
30May